We describe the use of an immunofluorescence assay and coculture to confirm human T-cell leukemialymphoma virus (HTLV) infection. Peripheral blood mononuclear cells from 32 of 32 seropositive donors were positive in the immunofluorescence assay, and 63% of their cocultures produced p24 antigen. Specific antibodies distinguished HTLV type I (HTLV-I) from HTLV-II. HTLV-I or HTLV-II was isolated from donors with indeterminate serologic test results.
Human T-cell leukemia-lymphoma virus type I (HTLV-I) causes leukemia and a neurologic syndrome, HTLV-associated myelopathy (3, 8, 24 ; reviewed in reference 9). Serologic testing for HTLV-I is routine in U.S. blood centers and is used diagnostically in patients with leukemia or HTLVassociated myelopathy (4, 28) . Many seropositive donors are actually infected with a related virus, HTLV-II (11, 19) , which has been associated with an HTLV-associated myelopathy-like illness as well (10) . Positive enzyme-linked immunosorbent assays (ELISAs) are followed by confirmatory testing by HTLV-I Western immunoblotting (WB) and, in some cases, by radioimmunoprecipitation assay (1, 4) . Definitive diagnosis by WB or radioimmunoprecipitation assay requires serologic recognition of at least two antigens (p24fas and an env gene product) of HTLV-I; any other seroreactivity is considered indeterminate (1, 4) .
Isolation of HTLV-I and HTLV-II has been described previously (5, 13, 14, 22, 26) . Peripheral blood mononuclear cells (PBMC) from infected patients are cocultivated with those from uninfected donors. The HTLVs produce low levels of reverse transcriptase, a useful marker for replication of other retroviruses. While culture has not been used extensively to diagnose HTLV, the polymerase chain reaction (PCR) is able to detect proviral DNA sequences present in PBMC in vivo and allows distinction of HTLV-I from HTLV-II (1, 2, 6, 7, 9-12, 15-19, 21, 26) .
PCR studies have shown that some persons with HTLV-I or HTLV-II infection are seronegative, and other infected patients have indeterminate WB results (15, 17, 19, 27) . One can rarely prove that a given PCR-positive sample represents true infection or contamination of the patient's PBMC DNA by previously amplified DNA. We sought to develop a method to verify positive PCR studies. To accomplish this, we determined the sensitivity of immunofluorescence assay (IFA) and coculture isolation of HThV-I and HTLV-II in blood from seropositive and seroindeterminate blood donors, using an antigen capture ELISA (AC-ELISA) to detect virus. We found that coculture and IFA studies helped us verify that positive PCR assays represent genuine infection.
Blood donors and serologic screening. All blood donors were tested for HTLV-I or HTLV-II antibody by ELISA after donation to the United Blood Services blood center in Albuquerque, N.M. Sera producing repeatedly positive results in the ELISA (Abbott Laboratories, North Chicago, Ill.) were used in WB analysis (Cambridge Biotech, Rockville, Md.) with lysates from HTLV-I-infected HUT-102 cells (1, 4, 20) . Lysates for WB contained added rgp2le, an HTLV-I envelope protein expressed in Escherichia coli (20 Electron microscopy. Cells were fixed in glutaraldehyde, postfixed in osmium tetroxide, dehydrated, and stained with uranyl acetate and lead citrate as described elsewhere (23) .
PCR. All individuals studied had been previously determined to have either HTLV-I or HTLV-II by PCR performed with tax and pol gene primers and probes as described elsewhere (11, 12, 18) .
Coculture assay for HTLV infection. PBMC from 32 seropositive donors were cultured. Figure 1 shows typical antigen production data for the cultures. Twenty cultures (63%) produced antigen after 1 to values near the reactive threshold value were rare, and positive cultures remained positive throughout the 4-week period. The results of the quantitative IFA for cells producing p19 antigen (performed on 18 cocultures) correlated well with the AC-ELISA results for antigen production (Fig. 2) . All cocultures from HTLV seropositive donors had at least a few p19-positive cells (Fig. 3) . Such cells represented 0.7 to 13% of all input cells. Those with high initial fraction of p19-positive cells (>8%) were much more likely to subsequently produce p24 antigen in coculture (Fig. 2) . The fraction of p19-positive cells increased in cultures for which the AC-ELISA was positive, while cultures that did not produce p24 antigen were uniformly nearly devoid of p19-positive cells by day 7. The fraction of p19-positive cells in AC-ELISA-positive cultures ranged from 12 to 57%.
That cultures producing AC-ELISA readings well above the background were productively infected with HTLV was HTLV-I-specific monoclonal antibody distinguishes HTLV-I from HTLV-II. Using the anti-p19 antibody from CPI, we could distinguish HTLV-I-producing cultures from those producing HTLV-II (Table 1) . Even HTLV-II cultures that had very high absorbance values with the Coulter antibody were negative with the CPI antibody (18) . (Table 2) . PBMC from 4 of the 15 seroindeterminate donors with negative PCR were also tested by coculture, and all failed to produce p24.
In HTLV coculture assays, PBMC from donors 3594 and 3958 produced p24 antigen (Fig. 1) . In the AC-ELISA for HTLV-I p19 antigen (CPI), the coculture from donor 3958 was positive while that from 3594 was not (Table 1) , and HTLV particles were observed in cocultures from both (reference 22 and data not shown). IFAs for p19 antigen were initially positive with PBMC from all four donors, but the p24 AC-ELISA was negative for cocultures from donors 3302 and 53814.
Repeat phlebotomies were performed on the three of the four WB-indeterminate donors at 17 months (donor 3302), 14 months (donor 3594), and 9 months (donor 3958). In the second sample, donor 3958 had small amounts of antibody to p19 and p24 and was thus considered to have seroconverted. In retrospective examination, extremely faint p24 and p19 reactivity was present originally but could be detected only with certain lots of WB strips. WBs of specimens from donors 3302 and 3594 remained essentially unchanged. None of the four had any risk for recent exposure to HTLV.
A method for HTLV culture suitable as an adjunct in diagnosis. Serologic assays are believed capable of detecting most infections with HTLV-I and HTLV-II, and some believe that infection is rare in blood donors who are seroindeterminate for HTLV-I and HTLV-II (17, 21) . However, previously reported experience with PCR includes several examples of apparent infection among individuals with indeterminate WB patterns or even a negative screening test (15, 17, 19, 27) . PCR can detect minute amounts of contaminating amplified DNA, and new viruses or endogenous viruses only slightly related to HTLV-I or HTLV-II could potentially be detected. We wished to determine whether an HTLV coculture assay using other methods of detection would improve the confidence with which we could diagnose infection in seronegative or seroindeterminate donors.
While the relatively low sensitivity (63%) of AC-ELISA combined with coculture may impose some limits on its ability to detect infection in serologically ambiguous donors, it still proved helpful in those situations in which it is positive.
Four of 19 donors with indeterminate serologic results whom we examined had PCR evidence of HTLV infection. Use of the coculture assay, including AC-ELISA and p19 immunofluorescence, demonstrated that (i) p19-positive cells were present in PBMC from all four, (ii) two of the four produced abundant p24 antigen, (iii) viral particles resembling HTLV were observed in the two cultures that were producing p24, and (iv) reactivity to the HTLV-I-specific anti-p19 antibody in p24-positive supematants was consistent with PCR viral typing. Thus, some WB-indeterminate blood donors are infected with an HTLV, and our results suggest that HTLV can be propagated from the cells of PCR-positive, WB-indeterminate donors at a frequency similar to those from serologically confirmed donors.
